ARTICLE | Finance

MS movers

Tracking multiple sclerosis stocks after FDA OKs oral treatment from Novartis

September 27, 2010 7:00 AM UTC

Shares of several multiple sclerosis companies moved last week after FDA approved Gilenya fingolimod from Novartis AG (NYSE:NVS; SIX:NOVN). The once-daily sphingosine 1-phosphate (S1P) receptor agonist is the first oral alternative for treating relapsing forms of the disease.

Merck KGaA (Xetra:MRK) was down €1.57 to €70.65 on Wednesday, the day Gilenya was approved, then lost €7.18 to €63 on Friday after EMA's CHMP recommended against approval of the pharma's oral competitor...